EUVIMEDEUVIMED entdecken
Crossref

Structure-Based Drug Design of Novel Indazole/Indolinone-Based Biaryl Derivatives as Oral IRAK4 Inhibitors for the Treatment of Inflammatory Diseases

Zhenwei Zhang, Xue Wang, Xuan Luo, Cong Li, Zesheng Liu, Chunmei Xia, Leyi Yu, Xiaowei Chen, Yaqian Sun, Peipei Wang, Lixin Gao, Xinyue Cao und 7 weitere

Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18255-18276

DOI: 10.1021/acs.jmedchem.6c00667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.07.2026. Verfasst von Zhenwei Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou310024, Ch…. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Indazoles, Drug Design, Protein Kinase Inhibitors. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, Key Technology Research and Development Program of Shandong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathological inflammation in multiple diseases arises from dysregulated innate immune signaling, wherein the interleukin-1 receptor-associated kinase 4 (IRAK4) acts as a critical node that mediates pro-inflammatory cascades and cytokine release downstream of toll-like and interleukin-1 receptors (TLR/IL-1R). Consequently, the therapeutic inhibition of IRAK4 using small molecules has emerged as a promising strategy for these conditions, particularly, rheumatoid arthritis. In this study, we identified a series of novel IRAK4 inhibitors featuring an indazole/indolinone-based biaryl scaffold, and forty-seven novel compounds were designed and synthesized using structure-based rational drug design strategies. Notably, compound 43 exhibited potent molecular and cellular IRAK4 inhibitory activities as well as in vivo anti-inflammatory activities in both LPS-induced acute inflammation and collagen-induced arthritis models alongside favorable pharmacokinetic properties. These findings indicated that compound 43 is a valuable lead compound for further structural optimization and the development of novel IRAK4-targeted anti-inflammatory therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1 Receptor-Associated KinasesIndazolesDrug DesignProtein Kinase InhibitorsInflammationAnti-Inflammatory AgentsOxindolesAnimalsStructure-Activity RelationshipArthritis, ExperimentalHumansMiceLipopolysaccharidesAdministration, OralRatsMale

Substanzen

Interleukin-1 Receptor-Associated KinasesIndazolesProtein Kinase InhibitorsAnti-Inflammatory AgentsIRAK4 protein, humanLipopolysaccharidesOxindoles

Autor:innen und Institutionen

  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou310024, China.
  • Drug Discovery & Development Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai201203, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong264117, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing210023, China.
  • State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai201203, China.
  • University of Chinese Academy of Sciences, Beijing100049, China.

ORCID-Profile: Hong Liu, Shengbin Zhou, Yu Zhou

Förderung

  • Natural Science Foundation of Shanghai Municipality
  • Key Technology Research and Development Program of Shandong Province
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Shandong Province
  • Taishan Scholar Foundation of Shandong Province
  • Innovative Drug Research and Development National Science and Technology Major Project
  • Xinjiang Talent Development Fund Project

Zitieren

APA

Zhang, Z., Wang, X., Luo, X., Li, C., Liu, Z., Xia, C., Yu, L., Chen, X., Sun, Y., Wang, P., Gao, L., Cao, X., Zhang, Y., Wang, Y., Liu, H., Sun, Y., Zhou, S., Li, J., & Zhou, Y. (2026). Structure-Based Drug Design of Novel Indazole/Indolinone-Based Biaryl Derivatives as Oral IRAK4 Inhibitors for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry, 69(15), 18255-18276. https://doi.org/10.1021/acs.jmedchem.6c00667

Vancouver

Zhang Z, Wang X, Luo X, Li C, Liu Z, Xia C, et al. Structure-Based Drug Design of Novel Indazole/Indolinone-Based Biaryl Derivatives as Oral IRAK4 Inhibitors for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry. 2026;69(15):18255-18276. doi:10.1021/acs.jmedchem.6c00667

BibTeX
@article{Zhang2026,
  author = {Zhang, Zhenwei and Wang, Xue and Luo, Xuan and Li, Cong and Liu, Zesheng and Xia, Chunmei and Yu, Leyi and Chen, Xiaowei and Sun, Yaqian and Wang, Peipei and Gao, Lixin and Cao, Xinyue and Zhang, Yufei and Wang, Yibing and Liu, Hong and Sun, Yili and Zhou, Shengbin and Li, Jia and Zhou, Yu},
  title = {Structure-Based Drug Design of Novel Indazole/Indolinone-Based Biaryl Derivatives as Oral IRAK4 Inhibitors for the Treatment of Inflammatory Diseases},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {15},
  pages = {18255--18276},
  doi = {10.1021/acs.jmedchem.6c00667}
}
Kostenlos starten →